| Title: | (Apo)Lipoprotein Profiling with Multi-Omics Analysis Identified Medium-HDL-Targeting PSRC1 with Therapeutic Potential for Coronary Artery Disease |
| Journal: | Advanced Science |
| Published: | 22 Feb 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/39985383/ |
| DOI: | https://doi.org/10.1002/advs.202413491 |
Publication 15884
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Identification of (apo)lipoprotein subclasses causally underpinning atherosclerosis may lead to identification of novel drug targets for treatment of atherosclerotic cardiovascular disease (ASCVD). In this study, observational and genetic associations between (apo)lipoprotein profile and carotid intima-media thickness-assessed atherosclerosis, and risks of coronary artery disease (CAD) and ischemic stroke (IS) are assessed, using data from the UK Biobank study, with further exploration of potential drug target for these two ASCVD subtypes through multi-omics analysis integrating genetic, transcriptomic, and proteomic data. Cholesteryl ester content in medium high-density lipoprotein causally protective of atherosclerosis is identified, plus a target gene, PSRC1, with therapeutic potential for CAD, but not IS, supported by consistent evidence from multi-omics layers of data, which also reveals that such therapeutic potential may be through downregulation of circulating proteins including TRP1, GRNs, and Pla2g12b, and upregulation of Neo1. The results provide strong evidence as well as mechanistic clues of PSRC1's therapeutic potential for CAD.</p>
9 Authors
- Yingmei Li
- Sihan Wang
- Ling Liu
- Hao Cai
- Yacan Huang
- Mingjing Gao
- Xiaogang Zhang
- Qingqing Wu
- Gaokun Qiu
1 Application
| Application ID | Title |
|---|---|
| 88159 | Fine-mapping, genetic correlation and genetic risk prediction for complex traits in different populations |
Enabling scientific discoveries that improve human health